Cardiovascular

Cardiology – Acute Myocardial Infarction (AMI)
Cesca is developing a proprietary, point-of-care autologous stem cell-based therapy intended as an adjunct treatment for patients who have suffered an acute ST-elevated myocardial infarction (“STEMI”), the most serious type of heart attack. Such treatments are aimed at minimizing the adverse remodeling of the heart post-STEMI.
TotipotentRX Cell Therapy Pvt. Ltd.
312A, Suncity Success Tower, Sec - 65, Gurugram - 122001, Haryana, India.
Tel.: +91 124 2841360/1361